Takeda Oncology Subsidiary Announces Promising Results For Brentuximab Vedotin
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical Co. Ltd. oncology subsidiary Millennium and Seattle Genetics announced positive Phase II study results for antibody drug Adcetris (brentuximab vedotin) in relapsed or refractory Hodgkin lymphoma patients